Navigation Links
INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model
Date:10/6/2010

INTERCIM Received a New Patent for a Non-statistical Approach... -- ST. PAUL, Minnesota and PARIS, October 6, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Internet Technology, Computer Electronics, Computer Software, Biotechnology, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model

   

Company Awarded Patent # 7,617,171 B2

ST. PAUL, Minnesota and PARIS, October 6, 2010 /PRNewswire/ -- Intercim, LLC, a global leader in manufacturing operation management (MOM) software, announced it has been awarded a patent called "Process for the iterative construction of an explanatory model".

This patented process is a key component of the Intercim Operations Intelligence technology and will help industrial manufacturers and life sciences researchers in two ways: unlike a statistics-based approach, it reuses existing information to optimize the length and cost of an experiment plan and it gives a quick and effective way to confirm the reliability of a discovery with only a few experiments.

This approach enables Pertinence Suite's users to get, much faster, a more reliable explanatory model even with limited data points available in a highly multi-dimensional non-euclidian space.

"This approach seems much easier to adopt than other standard Design of Experiment techniques, because we can analyze simultaneously the influence of many design parameters without statistical hypotheses. Thanks to the Interactive Experiment Planning of Process Rule Discovery(TM), we have reduced our need for physical experiments by 50% and sometimes more," says Dominique Veret, former Head of Development at Siemens Automotive Hydraulics, now Continental.

In the last 18 months, Intercim has received several additional patents which validate the uniqueness of Intercim's logic-based analytics for rule discovery and rule-based real-time predictions on complex systems and industrial processes. The announcement of this latest patent further demonstrates the unprecedented value proposition that Intercim offers to the market in terms of Operations Intelligence. John Todd, Intercim's CEO adds, "This patent confirms that Intercim truly offers a unique and high value-add capability. This latest Patent award helps validate Intercim's contribution to improved complex system understanding, manufacturing productivity and cycle time optimization for our key markets: Aerospace & Defense, Automotive and Life Sciences."

About Intercim

Intercim has a 27-year history of helping advanced and highly regulated manufacturers reach their business goals through best in class software solutions. Early 2009, Dassault Systemes a world leader Product Lifecycle Management took a minority position in Intercim. For the first time, the combination of Intercim's software capabilities with the virtual experience provided by Dassault Systemes' solutions allows this type of mission-critical collaboration and knowledge sharing. Intercim serves industry-leading customers such as Boeing, EADS, Areva, Intel, Sanofi-Pasteur, BMW, and Honeywell.


'/>"/>
SOURCE Intercim
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
2. MIT is pleased to announce that it has received a US$ 500,000 private placement from its Chinese partners
3. MIT is pleased to announce that it has received clearance by FINRA to be listed on the OTC Bulletin Board "MDLH.OB"
4. MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
5. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
6. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
7. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
8. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
9. Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
10. PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKessons Patent Application
11. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Drug Discovery Services portfolio to include an array of biochemical analyses critical ... reliable data to drive their hit-to-lead and SAR programs, including inhibitor potency and ...
(Date:2/23/2017)... 23, 2017  In Atlanta, it seems everyone has a ... intertwine to create an expressive and dynamic community unlike any ... and contribute to it. With their newest ... seeks to carry on that tradition with a unique, ... salon is the newest of 13 nationwide locations, ...
(Date:2/23/2017)... San Antonio, TX (PRWEB) , ... February 23, ... ... and Drug Administration (FDA) de novo clearance to begin marketing the SPEAC® System, ... is indicated for adults at home or in healthcare facilities during periods of ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... studies (such as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or ... Salivary Insulin Assay from Salimetrics’ SalivaLab , the relationship between insulin and ...
Breaking Biology Technology:
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):